Connect with us

Politics

Coronavirus Upends Marijuana, Psychedelics And Drug Reform Ballot Measures

Published

on

Marijuana and drug policy reform advocates came into 2020 believing it would be a big—and perhaps unprecedented—year for legalization and decriminalization measures on state ballots. From California to Missouri to Oregon, they had high hopes for placing far-reaching initiatives before voters in November.

But many of those efforts have been severely impeded by the coronavirus pandemic, which has made mass signature gathering to qualify ballot measures all but impossible as public health and government officials have urged social distancing measures.

Here’s a look at the growing list of ballot initiatives on cannabis and broader drug reforms that have been effectively halted by the COVID-19 outbreak.

California

Separate campaigns to amend California’s legal marijuana program and legalize psilocybin mushrooms are calling on officials to allow them to collect ballot signatures digitally instead of in-person due to the health risks of the the latter traditional route amid the pandemic. So far those requests seem to have been ignored.

Missouri

Activists in Missouri announced that they have “no practical way” of collecting enough signatures to place a marijuana legalization measure before voters amid the pandemic and are now considering shifting their focus to the 2022 election.

Nebraska

A campaign working to qualify a medical cannabis measure for the November ballot is temporarily suspending signature gathering efforts during the coronavirus outbreak “out of an abundance of caution.”

Oregon

Activists behind a measure to decriminalize possession of all drugs and expand treatment services using current marijuana tax revenue has halted in-person signature collection efforts. That said, the campaign says it has almost enough to qualify and so is urging supporters to download, print, sign and mail petitions to help. Also in Oregon, a separate team of advocates working to legalize the therapeutic use of psilocybin mushrooms has also suspended mass signature collection efforts despite similarly having almost enough to ensure ballot access. They are asking people who want to sign to fill out an online form so that petitions can be mailed to them.

Washington, D.C.

Activists in the nation’s capital were hoping to give voters a chance to decide on a measure to effectively decriminalize a wide range of psychedelics—including psilocybin, ayahuasca and ibogaine—in November. But they, like their colleagues in states across the country, have acknowledged that the COVID-19 pandemic makes in-person signature collection virtually impossible. They’ve asked for a change in the law to allow for electronic petition signing, but officials have demurred, and so the campaign is now exploring a plan to mail petitions to supporters who would then collect signatures from their immediate family members and close friends.

Beyond the ballot, the coronavirus outbreak has also impeded efforts to advance marijuana reform bills through state legislatures in place like Connecticut, New York and Vermont as sessions have been largely halted due to health concerns.

But it’s not all bad news for cannabis reform advocates in 2020.

In South Dakota, separate measures to legalize marijuana and allow medical cannabis have already qualified for the state’s November ballot. That said, advocates there are now urging voters to consider signing up to receive absentee ballots in case an extended pandemic complicates efforts to get to polling places come Election Day.

In Mississippi, the state certified that advocates collected a sufficient number of signatures to place a medical marijuana legalization question before voters—though lawmakers recently approved a more restrictive cannabis measure that will appear alongside and compete with the activist-driven one.

In New Jersey, the legislature voted late last year to place a marijuana legalization referendum on the November ballot.

And in Arizona, activists announced last week that they have already collected more signatures than needed to qualify a marijuana legalization measure for the ballot—though they have not yet been submitted to and verified by the state.

At the same time, most states with legal marijuana programs have deemed cannabis dispensaries and cultivation operations to be “essential” and thus exempt from orders mandating that most other businesses temporarily close down amid the coronavirus pandemic—a move that further highlights how the industry has become a mainstream part of American commerce.

Meanwhile, several of the other yet-to-be qualified measures listed above are very close to having enough signatures to make it onto their respective states’ ballots though it remains to be seen if officials will approve electronic petitioning methods as a means of safely collecting enough valid signatures or if the campaigns will be able to bring in sufficient support through other means such as targeted mailing of petitions to prospective signers.

This piece was first published by Forbes.

Photo courtesy of Democracy Chronicles.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Tom Angell is the editor of Marijuana Moment. A 20-year veteran in the cannabis law reform movement, he covers the policy and politics of marijuana. Separately, he founded the nonprofit Marijuana Majority. Previously he reported for Marijuana.com and MassRoots, and handled media relations and campaigns for Law Enforcement Against Prohibition and Students for Sensible Drug Policy. (Organization citations are for identification only and do not constitute an endorsement or partnership.)

Politics

USDA Announces Hemp Policy Changes To Improve Insurance Coverage For Producers

Published

on

The U.S. Department of Agriculture (USDA) on Thursday announced that it has taken steps to improve insurance policies for hemp businesses, making them more flexible in response to stakeholder feedback.

USDA’s Risk Management Agency (RMA) said it is making it so hemp producers are no longer mandated to deliver their crop “without economic value for insurability.” It further amended policy to clarify how the “amount of insurable acreage is determined if the processor contract specifies both an acreage and a production amount.”

“This change was made in the policy to ensure producers know how their insurable acreage is determined for those contracts,” the agency said in a press release.

RMA Administrator Marcia Bunger said that hemp is “an emerging crop, and we are working with hemp producers to provide insurance options that make sense for producers and for insurance providers.”

“RMA has worked to expand and refine our offerings to be responsive and dynamic,” she said.

The department also said it has added a requirement for producers who grow hemp directly from seeds that are planted in the ground.

“Before insurance attaches, producers must have acreage inspected and must have a minimum of 1,200 live plants per acre,” it explained. “This requirement was added to align direct-seeded hemp with the common farming practice for transplanted Cannabidiol (CBD) of transplanting at least 1,200 live plants per acre.”

The policy changes were outlined in a bulletin that was published on Tuesday. The department also released updated insurance standards and crop loss adjustments handbooks, as well as a detailed summary of the changes.

USDA has taken a number of steps to align hemp insurance policies with those of other lawful crops since the plant was federally legalized under the 2018 Farm Bill, consistently seeking out input from stakeholders as the industry matures.

Last year, for example, the department made it so hemp farmers can qualify for Multi-Peril Crop Insurance, in addition to several other coverage programs for which the crop is now eligible.

As it stands, federal hemp crop insurance programs are available in select counties in 25 states. This year alone, “hemp producers insured 12,189 acres and 59 policies to protect $10.9 million in liabilities,” USDA said.

As part of its overall outreach, the department launched a large-scale survey in August to gain insight into the hemp market that’s emerged.

After requesting permission from the White House earlier this year to conduct the survey of about 20,000 hemp farmers, the agency’s National Agricultural Statistics Service recently said that the forms are being finalized to be filled out via mail or online.

USDA is asking questions about plans for outdoor hemp production, acreage for operations, primary and secondary uses for the crop and what kinds of prices producers are able to bring in. The questionnaire lists preparations such as smokeable hemp, extracts like CBD, grain for human consumption, fiber and seeds as areas the department is interested in learning about.

Last year, USDA announced plans to distribute a separate national survey to gain insights from thousands of hemp businesses that could inform its approach to regulating the industry.

That survey is being completed in partnership with National Association of State Departments of Agriculture and the University of Kentucky. The department said it wanted to learn about “current production costs, production practices, and marketing practices” for hemp.

There’s still much to learn about the burgeoning market, even as USDA continues to approve state regulatory plans for the crop. Recently, the agency approved a hemp plan submitted by Colorado, where officials have consistently insisted that the state intends to be a leader in the space.

While USDA’s final rule for hemp took effect on March 22, the agency is evidently still interested in gathering information to further inform its regulatory approach going forward. Industry stakeholders say the release of the final rule is a positive step forward that will provide businesses with needed guidance, but they’ve also pointed to a number of policies that they hope to revise as the market matures such as USDA’s hemp testing requirements.

The federal Small Business Administration’s Office of Advocacy expressed a similar sentiment in a blog post in February, writing that it is “pleased with some of the changes that [USDA] has made to the rule, as they offer more certainty and are less burdensome to small farmers,” but “some concerns remained unaddressed in the final rule.”

USDA announced in April that it is teaming up with a chemical manufacturing company on a two-year project that could significantly expand the hemp-based cosmetics market.

Meanwhile, the U.S. Department of Energy (DOE) announced in August that it is sponsoring a project to develop hemp fiber insulation that’s designed to be better for the environment and public health than conventional preparations are.

DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT

Photo courtesy of Brendan Cleak.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

GOP Congressman And AOC Team Up On Marijuana Bill To Incentivize State-Level Expungements

Published

on

As congressional lawmakers work to advance federal marijuana legalization, a bipartisan duo on Thursday filed a bill that would incentivize states and local governments to expunge cannabis records in their jurisdictions.

Reps. Dave Joyce (R-OH) and Alexandria Ocasio-Cortez (D-NY) are sponsoring the legislation, titled the Harnessing Opportunities by Pursuing Expungement (HOPE) Act.

It would encourage states to provide relief to people with non-violent marijuana convictions through federal grants—the State Expungement Opportunity Grant Program, run through the Department of Justice—that would help cover the administrative costs of identifying and clearing eligible cases. The bill proposes to appropriate $2 million in funding to support the program for each fiscal year starting in 2023 and ending in 2032.

Specifically, the grants could be used by states to purchase technology used to facilitate expungements at scale, automate the relief process, fund legal clinics to help people get their records cleared and support “innovative partnerships” to provide mass relief.

“Having been both a public defender and a prosecutor, I have seen first-hand how cannabis law violations can foreclose a lifetime of opportunities ranging from employment to education to housing,” Joyce said in a press release. “The collateral damage caused by these missed opportunities is woefully underestimated and has impacted entire families, communities, and regional economies.”

“By helping states establish and improve expungement programs for minor cannabis offenses, the HOPE Act will pave the way for expanded economic opportunities to thrive alongside effective investments to redress the consequences of the War on Drugs,” the congressman said.

Ocasio-Cortez said that “as we continue to advocate for the decriminalization and legalization of marijuana, this bipartisan bill will provide localities the resources they need to expunge drug charges that continue to hold back Americans, disproportionately people of color, from employment, housing and other opportunity.”

 

Under the bill, state governors and local governments “shall submit to the attorney general an application at such time, in such manner, and containing such information as the attorney general may reasonably require” to qualify for the grants.

Further, the legislation would require the attorney general to carry out a study on the impacts of cannabis convictions on individuals, as well as the financial costs for states that incarcerate people over non-violent marijuana offenses.

Officials in jurisdictions that receive the grants would be required to “publish on a publicly accessible website information about the availability and process of expunging convictions for cannabis offenses, including information for individuals living in a different jurisdiction who were convicted of a cannabis offense in that jurisdiction.”

They would also need to “submit to the attorney general a report describing the uses of such funds, and how many convictions for cannabis offenses have been expunged using such funds.”

While the proposal wouldn’t end federal marijuana prohibition, it would help facilitate relief at the state level where most cannabis arrests take place in the U.S.

The bill also holds bipartisan appeal. It’s an important, albeit incremental, move to right the wrongs of the drug war, as progressives have been fighting for; it’s also narrowly tailored, simply giving an incentive to states to enact a reform that has majority support among the public.

“This bipartisan effort represents the growing consensus to reform marijuana policies in a manner that addresses the harms inflicted by prohibition,” NORML Political Director Justin Strekal said. “It provides cash assistance for state and localities that are wisely choosing to remove these stigmatizing records. There is no justification for continuing to prevent tens of millions of Americans from fully participating in their community and workforce simply because they bear the burden of a past marijuana conviction.”

“Ultimately, efforts to provide necessary relief to those who carry the scarlet letter of a marijuana conviction must be carried out primarily by state and local officials,” he said. “Having this federal incentive available will go a long way toward empowering local leaders and citizens to take these steps to address the past injustices brought about by the failed policy of marijuana prohibition, and will also move us closer toward embracing more reasonable cannabis policies.”

What’s more, while there’s been an open question about what President Joe Biden would do with a broad marijuana reform bill if it arrived on his desk given his ongoing opposition to adult-use legalization, he’s repeatedly said that nobody should be incarcerated over cannabis and that records should be expunged, so this proposal could potentially garner his favor.

There’s a similar provision to incentivize state-level expungements included in the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act that cleared the House Judiciary Committee in September. But that legislation is far more wide-ranging in that it would federally deschedule cannabis.

Meanwhile, Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR) and Sen. Cory Booker (D-NJ) are finalizing their own bill to federally legalize marijuana.

More recently, GOP lawmakers filed a legalization bill that is being framed as a compromise between progressive proposals and more scaled-back legislation that Republican legislators have introduced in recent sessions. It also contains expungements provisions.

Read the full text of the new marijuana expungements bill below:

Click to access hope-act-mm-copy.pdf

Top Federal Drug Official Personally Hesitates To Study Marijuana Because Of Schedule I Research Barriers

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT

Published

on

The Drug Enforcement Administration (DEA) has yet again increased its quota for the legal production of illegal controlled substances like psilocybin, MDMA and DMT for research purposes in 2022.

In a notice published in the Federal Register on Thursday, the agency made another quota adjustment for certain psychedelics. This has become something of a theme both for 2021 and 2022 production goals, with DEA raising the amounts in response to increased interest and demand within the scientific community.

Take psilocybin, for example. When DEA first released its 2021 quota for the psychedelic compound, it said it wanted just 30 grams for the year. Now that number has been boosted to 8,000 grams for 2022—a 26,567 percent increase.

“The [aggregate production quotas] established today reflect DEA’s estimates of the medical, scientific, research, and industrial needs of the United States for 2022, as well as lawful export requirements and establishment and maintenance of reserve stocks,” the agency said. “DEA can adjust the established APQs if these needs change.”

“For instance, if DEA receives additional research protocols from DEA-registered researchers, or additional quota applications from DEA-registered manufacturers, DEA will consider revising the APQ,” it explained. “DEA did receive additional quota applications from DEA-registered manufacturers for 5-MEO-DMT, psilocybin, and MDMA.”

DEA’s quota for MDMA more than doubled since it first proposed its 2022 target number, increasing from 3,200 grams to 8,200 grams. Going back to the agency’s initial 2021 quotas, it originally wanted just 50 grams of MDMA.

DMT is another apparent drug of interest within the research and medical communities, with DEA adjusting its 2022 quota from 250 grams to 3,000 grams. In further contrast, the agency’s first 2021 APQ called for only 50 grams of DMT.

When it comes to 5-MeO-DMT, DEA initially wanted just 35 grams for 2021, but that has now been ramped up significantly to 2,550 grams for 2022.

In the new notice, DEA also said that it received feedback from indigenous communities regarding the production of certain substances that are used ceremonially. For example, the Native American Church of North America submitted a comment concerning mescaline.

“They commented that their peyote ceremonies are contingent on the continued availability of peyote in the wild for sacramental use, and that the non-Native use of mescaline in research and clinical studies will have a direct impact upon the church’s ability to use, purchase, transport, and possess peyote pursuant to the American Indian Religious Freedom Act (AIRFA), as it will lead to commercialization and exploitation of peyote across its natural range and potential reclassification of its scheduling status,” DEA said.

The agency explained in its response that it is not proposing the manufacturing of peyote-derived mescaline, however, and instead will be relying on synthetic forms of the substance. “Thus, the 2022 APQ for mescaline does not have any material effect on the use of peyote by members of the Native American Church,” it said.

All told, the final quotas represent welcome news for researchers and advocates. It shows a willingness from the leading federal drug enforcement agency to recognize an emerging scientific field and promote studies into the substances regardless of their Schedule I status.

See the full list of DEA production quotas for certain drugs for 2021 and 2022 as proposed and revised below:

Substance 2021 initial 2021 revised 2021 final 2022 initial 2022 final
Psilocybin 30 1,500 6,000 3,000 8,000
Psilocyn 50 1,000 3,500 2,000 4,000
MDMA 50 50 3,200 3,200 8,200
DMT 50 50 3,200 250 3,000
LSD 40 40 40 500 500
Mescaline 25 25 25 100 100
5-MeO-DMT 35 35 35 550 2,550
MDA 55 55 55 200 200
Marijuana 1,500,000 2,000,000 2,000,000 3,200,000 3,200,000
Marijuana extract 200,000 500,000 500,000 1,000,000 1,000,000
All other tetrahydrocannabinol 1,000 1,000 1,000 2,000 2,000

And meeting the 3.2 million gram production goal for marijuana for 2022 in particular could be simplified now that DEA has decided to end the current monopoly on federally authorized cannabis manufacturing that the University of Mississippi has had for half a century by approving additional growers for research.

National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.

But while the production developments are promising, advocates are still frustrated that these plants and fungi remain in the strictest drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.

A federal appeals court recently dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.

Meanwhile, DEA has given hemp businesses that sell delta-8 THC products a boost, with representatives making comments recently signaling that, at the federal level at least, it’s not a controlled substance at this time.

Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.

Top Federal Drug Official Personally Hesitates To Study Marijuana Because Of Schedule I Research Barriers

Photo courtesy of Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment